Trial Profile
Pilot Study of Daily Exemestane in Women With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs Exemestane (Primary)
- Indications Atypical endometrial hyperplasia; Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- 23 Dec 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.
- 15 Apr 2023 Planned End Date changed from 31 Mar 2023 to 30 Jun 2023.
- 15 Apr 2023 Planned primary completion date changed from 31 Mar 2023 to 30 Jun 2023.